Anticoagulant Efficacy and Immunogenicity of the Selective Factor Xa Inhibitor Antistasin Following Subcutaneous Administration in the Rhesus Monkey

Summary

The antithrombotic efficacy and duration of action of a single subcutaneous administration of the selective factor Xa inhibitor recombinant antistasin (rATS) was evaluated in a rhesus monkey model of mild disseminated intravascular coagulation. rATS (1 mg/kg) was shown to be fully effective and comparable to standard heparin (1,000 U/kg) in the suppression of thromboplastin-induced fibrinopeptide A generation for at least 5 h following a single subcutaneous administration. The absorption rate of rATS, as measured by ex vivo activated partial thromboplastin times (aPTT), mirrored that of standard heparin exhibiting peak anticoagulant activity between 1 and 2 h post administration. The anticoagulant effects of a single rATS dose lasted for longer than 30 h maintaining an aPTT value at least 2-fold higher than baseline. Repeated subcutaneous administrations of rATS resulted in the generation of fully neutralizing antibodies. These results suggest that specific factor Xa inhibition may be as effective as standard heparin in the treatment of venous thrombosis. Due to its antigenicity however, rATS is probably not suitable for chronic subcutaneous anticoagulant therapy.

• References

• 1 Hirsh J. Heparin. Drug Therapy 1991; 324: 1565-1574
• 2 Hull R, Delmore T, Genton E. et al Warfarin sodium versus low-dose heparin in the long term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-858
• 3 Hull R, Raskob G, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenblum D, Sackett DL, Anderson C, Harrison L, Gent M. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med 1986; 315: 1109-1114
• 4 Salzman EW, Deykin D, Shapiro RM, Rosenberg R. Management of heparin therapy: controlled prospective trial. N Engl J Med 1975; 292: 1046-1050
• 5 Colditz GA, Tuden RL, Oster G. Rates of venous thrombosis after general surgery: combined results of randomized clinical trials. Lancet 1986; ii: 143-146
• 6 Feinstein DI. Diagnosis and management of disseminated intravascular coagulation: The role of heparin therapy. Blood 1982; 60: 284-287
• 7 Blauhut B, Kramer H, Vinazzer H, Bergmann H. Substitution of antithrombin III in shock and DIC: A randomized study. Thromb Res 1985; 39: 81-89
• 8 Glazier RL, Crowell EB. Randomized prospective trial of continuous vs intermittent heparin therapy. JAMA 1976; 236: 1365-1367
• 9 Bentley PG, Kakkar VV, Scully MF, MacGregor IR, Webb P, Chan P, Jones N. An objective study of alternative methods of heparin administration. Thromb Res 1980; 18: 177-187
• 10 Andersson G, Fagrell B, Holmgren K, Johnson H, Ljungberg B, Wilhelmmsson S. Antithrombin III in patients with deep vein thrombosis during heparin treatment (subcutaneous and intravenous) and during and after treatment with oral coumarins. Thromb Res 1984; 34: 333-338
• 11 Walker MG, Shaw JW, Thompson GJL, Cumming JGR, Lea Thomas M. Subcutaneous calcium heparin versus intravenous sodium heparin in treatment of established acute deep-vein thrombosis of the legs: a multicenter prospective randomized trial. Br Med J 1987; 294: 1189-1192
• 12 Doyle DJ, Turpie AGG, Hirsh J, Best C, Kinch D, Levine MN, Gent M. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep-vein thrombosis. Ann Intern Med 1987; 107: 441-445
• 13 Pini M, Pattacini C, Quintavalla R, Poli T, Megha A, Tagliaferri A, Manotti C, Dettori AG. Subcutaneous versus intravenous heparin in the treatment of deep vein thrombosis - A randomized clinical trial. Thromb Haemostas 1990; 64: 222-226
• 14 Raskob GE, Carter CJ, Hull RD. Heparin therapy for venous thrombosis and pulmonary embolism. Blood Rev 1988; 2: 251-258
• 15 Kelton JG, Levine MN. Heparin-induced thrombocytopenia. Semin Thromb Hemostas 1986; 12: 59-64
• 16 Walker AM, Jick H. Predictors of bleeding during heparin therapy. JAMA 1980; 244: 1209-1212
• 17 Cines DB, Kaywin P, Bina M. et al Heparin-associated thrombocytopenia. N Engl J Med 1980; 303: 788-795
• 18 Dawes J, Prowse CV, Pepper DS. Absorption of heparin, LMW heparin and SP54 after subcutaneous injection, assessed by competitive binding assay. Thromb Res 1986; 44: 683-693
• 19 Bergquist D, Hedner U, Sjorin E, Holmer E. Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously. Thromb Res 1983; 32: 381-391
• 20 Ockelford PA, Patterson J, Johns AS. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (fragmin). Thromb Haemostas 1989; 62: 1046-1049
• 21 Levine MN, Hirsh J. An overview of clinical trials of low molecular weight heparin fractions. Acta Chir Scand Suppl 1988; 543: 73-78
• 22 Kakkar VV, Murray JG. Efficacy and safety of low molecular weight heparin (CY 216) in preventing postoperative venous thromboembolism: A co-operative study. Br J Surg 1985; 72: 766-791
• 23 Turpie AGG, Levin MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M. A randomized controlled trial of low-molecular-weight heparin (Enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1987; 315: 925-929
• 24 Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of two low molecular weight heparins in rabbits. Blood 1982; 59: 1239-1245
• 25 Esquivel CO, Bergqvist D, Bjorck CG, Nilsson B. Comparison between commercial heparin, low molecular weight heparin and pentosan poly-sulphate on haemostasis and platelets in vivo. Thromb Res 1982; 28: 389-399
• 26 Holmer E, Matsson C, Nilsson S. Anticoagulant and antithrombotic effects of low molecular weight heparin fragments in rabbits. Thromb Res 1982; 25: 475-485
• 27 Andriuoli G, Mastucchi R, Barnti M, Sarret M. Comparison of the antithrombotic and hemorrhagic effects of heparin and a new low molecular weight heparin in the rat. Haemostasis 1985; 15: 324-330
• 28 Bergqvist D, Nilsson B, Hedner U, Pedersen PC, Ostergaard PB. The effects of heparin fragments of different molecular weights in experimental thrombosis and haemostasis. Thromb Res 1985; 38: 589-601
• 29 Bredden HK. Low molecular weight heparins and bleeding. Semin Thromb Hemostas 1989; 15: 401-404
• 30 Choay J. Structure and activity of heparin and its fragments: An overview. Semin Thromb Hemostas 1989; 15: 359-364
• 31 Ockelford PA, Carter CJ, Mitchell L, Hirsh J. Discordance between the anti-Xa activity and the antithrombin activity of an ultra-low molecular weight heparin fraction. Thromb Res 1982; 28: 401-409
• 32 Buchanan MR, Bonev B, Ofosu F, Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood 1985; 65: 198-201
• 33 Harenberg J. Relation of antifactor Xa activity of heparins and antithrombotic efficacy. Haemostasis 18 Suppl. 1988; 3: 13-18
• 34 Tuszynski G, Gasic T, Gasic G. Isolation and characterization of antistasin. J Biol Chem 1987; 262: 9718-9723
• 35 Nutt E, Gasic T, Rodkey J, Gasic G, Jacobs J, Friedman P, Simpson E. The amino acid sequence of antistasin. J Biol Chem 1988; 263: 10162-10167
• 36 Dunwiddie CT, Thornberry N, Bull H, Sardana M, Friedman P, Jacobs J, Simpson E. Antistasin, a leech-derived inhibitor of factor Xa: Kinetic analysis of enzyme inhibition and identification of the reactive site. J Biol Chem 1989; 264: 16694-16699
• 37 Nutt EM, Jain D, Lenny A, Schaffer L, Siegl P, Dunwiddie CT. Purification and characterization of recombinant antistasin: A leech-derived inhibitor of coagulation factor Xa. Arch Biochem Biophys 1991; 285: 37-44
• 38 Vlasuk GP, Ramjit D, Fujita T, Dunwiddie CT, Nutt EM, Smith DE, Shebuski RJ. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb Haemostas 1991; 65: 257-262
• 39 Neeper M, Waxman L, Smith D, Schulman C, Sardana M, Ellis R, Schaffer L, Siegl PK, Vlasuk GP. Characterization of recombinant tick anticoagulant peptide, a highly selective inhibitor of blood coagulation factor Xa. J Biol Chem 1990; 265: 17746-17752
• 40 Broze Jr GF, Leyham JE, Schwartz BD, Miletich JP. Purification of human brain tissue factor. J Biol Chem 1985; 260: 10917-10920
• 41 Zur M, Nemerson Y. Kinetics of factor IX activation via the extrinsic pathway, dependence of Km on tissue factor. J Biol Chem 1980; 255: 5703-5707
• 42 Boisclair MD, Ireland H, Lane DA. Assessment of hypercoagulable states by measurement of activation fragments and peptides. Blood 1990; 4: 25-30
• 43 Nossel HL, Yudelman I, Canfield RE, Butler JR VP, Spanondis K, Wilner GD, Quereshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43-48
• 44 Owen J, Friedman K, Grossman B, Wilkins C, Berke A, Powers E. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988; 72: 616-621
• 45 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin Ill-independent inhibitors. J Clin Invest 1990; 86: 385-391
• 46 Klocking HP, Guttner J, Fink E. Toxicological studies with recombinant hirudin. Folia Haematol 1988; 115: 75-82
• 47 Markwardt F, Nowak G, Sturzebecher J, Vogel G. Clinico-phar-macological studies with recombinant hirudin. Thromb Res 1988; 52: 393-399
• 48 Teitel SM, Rosenberg RD. Protection of factor Xa from neutralization by the heparin antithrombin-III complex. J Clin Invest 1983; 71: 1383-1391